A substantial proportion of migraine patients have gastric stasis and suffer severe nausea
and/or vomiting during their migraine attack. This may lead to erratic absorption from the …

Objectives To assess the effects of bimagrumab on skeletal muscle mass and function in
older adults with sarcopenia and mobility limitations. Design A 24‐week, randomized …

Importance Antibody blockade of activin type II receptor (ActRII) signaling stimulates skeletal
muscle growth. Previous clinical studies suggest that ActRII inhibition with the monoclonal …

Importance The potential benefit of novel skeletal muscle anabolic agents to improve
physical function in people with sarcopenia and other muscle wasting diseases is unknown …

Objectives To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B
cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary …

Aim To test the hypothesis that an improving body composition in insulin‐resistant
individuals could enhance insulin sensitivity. Methods A total of 16 people with a mean body …

Maladjusted immune responses to the coronavirus disease 2019 (COVID-19), for example,
cytokine release syndrome, may result in immunopathology and acute respiratory distress …

Background Spinal and bulbar muscular atrophy is an X-linked neuromuscular disease
caused by CAG repeat expansion in the androgen receptor gene. Patients with this disease …

Background Bimagrumab prevents activity of myostatin and other negative regulators of
skeletal muscle mass. This randomized double‐blind, placebo‐controlled study investigated …

Background Bimagrumab is a human monoclonal antibody inhibitor of activin type II
receptors (Act RII), with anabolic action on skeletal muscle mass by blocking binding of …